Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents.
Anticancer drugs that bind to DNA and inhibit DNA-processing enzymes represent an important class of anticancer drugs. Combilexin molecules, which combine DNA minor groove binding and intercalating functionalities, have the potential for increased DNA binding affinity and increased selectivity due to their dual mode of DNA binding. This study describes the synthesis of DNA minor groove binder netropsin analogs containing either one or two N-methylpyrrole carboxamide groups linked to DNA-intercalating anthrapyrazoles. Those hybrid molecules which had both two N-methylpyrrole groups and terminal (dimethylamino)alkyl side chains displayed submicromolar cytotoxicity towards K562 human leukemia cells. The combilexins were also evaluated for DNA binding by measuring the increase in DNA melting temperature, for DNA topoisomerase IIalpha-mediated double strand cleavage of DNA, for inhibition of DNA topoisomerase IIalpha decatenation activity, and for inhibition of DNA topoisomerase I relaxation of DNA. Several of the compounds stabilized the DNA-topoisomerase IIalpha covalent complex indicating that they acted as topoisomerase IIalpha poisons. Some of the combilexins had higher affinity for DNA than their parent anthrapyrazoles. In conclusion, a novel group of compounds combining DNA intercalating anthrapyrazole groups and minor groove binding netropsin analogs have been designed, synthesized and biologically evaluated as possible novel anticancer agents.
Zhang
Rui
R
Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0T5.
Wu
Xing
X
Guziec
Lynn J
LJ
Guziec
Frank S
FS
Chee
Gaik-Lean
GL
Yalowich
Jack C
JC
Hasinoff
Brian B
BB
D000577:Amides / Q000138:chemical synthesis* / Q000494:pharmacology; D018943:Anthracyclines / Q000138:chemical synthesis / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D004247:DNA / Q000737:chemistry / Q000378:metabolism*; D015195:Drug Design; D006801:Humans; D007364:Intercalating Agents; D020014:K562 Cells; D009429:Netropsin; D011758:Pyrroles
D000577:Amides; D018943:Anthracyclines; D000970:Antineoplastic Agents; D007364:Intercalating Agents; D011758:Pyrroles; D009429:Netropsin; D004247:DNA; C055925:anthrapyrazole
Prog Nucleic Acid Res Mol Biol. 2000;64:221-53
10697411
Bioorg Med Chem. 2009 Jul 1;17(13):4575-82
19457675
J Pharm Sci. 1989 Nov;78(11):910-7
2621573
Cancer Chemother Pharmacol. 2006 Jan;57(2):221-33
16010589
Biochem Pharmacol. 1997 Jun 15;53(12):1843-53
9256159
Curr Med Chem. 2005;12(24):2805-47
16305474
Chem Res Toxicol. 1993 Sep-Oct;6(5):585-97
8292734
Br J Cancer. 1994 Apr;69(4):687-97
8142256
Chembiochem. 2003 Jan 3;4(1):50-61
12512076
Anticancer Drug Des. 1995 Mar;10(2):131-54
7710635
J Chem Inf Model. 2006 Jul-Aug;46(4):1827-35
16859314
Bioorg Med Chem. 2008 Apr 1;16(7):3959-68
18258442
Acta Crystallogr D Biol Crystallogr. 1995 Mar 1;51(Pt 2):190-8
15299320
Biochem Pharmacol. 1996 Aug 23;52(4):635-42
8759037
Biochem Pharmacol. 1988 Dec 15;37(24):4727-33
2462423
Methods Enzymol. 2001;340:529-55
11494869
Mol Pharmacol. 2008 Mar;73(3):686-96
18045852
Biochem Pharmacol. 2004 Feb 15;67(4):631-42
14757163
Anticancer Drug Des. 1997 Sep;12(6):481-501
9311557
J Natl Cancer Inst. 1994 Aug 17;86(16):1239-44
8040892
Arch Biochem Biophys. 1995 Aug 1;321(1):51-60
7639535
Proteins. 2003 Sep 1;52(4):609-23
12910460
Mol Pharmacol. 1997 Nov;52(5):839-45
9351975
Mol Pharmacol. 1994 Jul;46(1):58-66
8058057
Mol Pharmacol. 1996 Feb;49(2):343-50
8632768
Bioconjug Chem. 1998 Sep-Oct;9(5):513-38
9736486
J Mol Biol. 1994 Jan 28;235(4):1218-30
8308885
Methods Mol Biol. 2001;95:283-9
11089240
Annu Rev Pharmacol Toxicol. 2001;41:53-77
11264450
Eur J Med Chem. 2007 Jun;42(6):752-71
17433851
Acta Crystallogr D Biol Crystallogr. 1993 Sep 1;49(Pt 5):458-67
15299505
Biopolymers. 1976 Jul;15(7):1345-75
949539
Biochim Biophys Acta. 1998 Oct 1;1400(1-3):83-105
9748515
Biochemistry. 1996 Apr 9;35(14):4251-64
8605173
Mol Pharmacol. 2005 Mar;67(3):937-47
15602006